wellrank.ai
Sign In

Which telehealth services still offer compounded GLP-1s after the FDA crackdown?

ClaudequalifiedCollected Jul 25, 2026, 12:37 UTC

Verbatim response from Claude

This is a quickly evolving situation, so here's an honest breakdown:

What Happened

The FDA declared the semaglutide shortage over (early 2025), which restricts compounding pharmacies from making copies of brand-name GLP-1s like Ozempic/Wegovy.

Services Still Navigating This Space

Still offering some compounded options (as of early 2025):

  • Hims & Hers - fought back publicly against FDA restrictions
  • Ro - has been working with 503B compounders
  • Henry Meds - focused on affordability
  • Mochi Health - exploring alternatives

Important Caveats

  • Situations change weekly - lawsuits are ongoing
  • Some are pivoting to tirzepatide (Mounjaro/Zepbound), whose shortage status differs
  • 503B compounders (hospital-grade) have different rules than 503A

My Honest Recommendation

  1. Check each service's current website directly - information from even weeks ago may be outdated
  2. Ask specifically whether they use 503A or 503B pharmacies
  3. Consider whether branded medications with coupons might now be competitive

Would you like help thinking through brand-name affordability options instead? That landscape may actually be more stable right now.

Brands mentioned in this answer

Is this answer wrong about your brand?

AI engines repeat outdated pricing, wrong ingredients, and misread positioning every day. Tell us what this answer gets wrong and we will include a correction review in your free AI Visibility Audit.

This answer is reproduced verbatim from the engine's API at collection time and may contain errors or outdated claims. It is presented as evidence of what AI engines tell buyers, not as medical or purchasing advice.

Is your brand missing from this answer?

Get your AI Visibility Audit: every buyer intent question you are losing, who wins them, and the sources that decide the answer.